Previous 10 | Next 10 |
2023-11-13 13:19:43 ET More on PAVmed PAVmed Inc. (PAVM) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed For further details see: PAVmed Q3 2023 Ea...
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day PR Newswire EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and ...
2023-11-06 15:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum PR Newswire Lishan Aklog , M.D., Chairman &am...
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Nov. 1, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "...
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection PR Newswire Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and fire...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lu...
2023-10-09 04:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference PR Newswire NEW YORK , Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage...
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection PR Newswire Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by mu...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luc...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...